keyword
https://read.qxmd.com/read/38669256/the-kras-atr-and-chek1-expression-levels-in-endometrial-cancer-are-the-risk-factors-predicting-recurrence
#1
JOURNAL ARTICLE
Liubov Buchynska, Inna Gordiienko, Nadiia Glushchenko, Nataliia Iurchenko
Endometrial cancer is the most prevalent gynecologic malignancy with a high risk of recurrence. Local recurrence occurs in 7-20% of patients with treated stage I cancer within 3 years after primary treatment. In this study, we found significantly elevated mRNA expression levels of the oncoprotein KRAS, along with two replicative stress markers, ATR and CHEK1, in samples of endometrial carcinomas of endometrium (ECE) from patients with relapse. In contrast, mRNA expression levels of the studied genes were low and uniform in samples from patients without relapse...
2024: PloS One
https://read.qxmd.com/read/38669163/succor-morbidity-complications-in-minimally-invasive-versus-open-radical-hysterectomy-in-early-cervical-cancer
#2
COMPARATIVE STUDY
Daniel Vázquez-Vicente, Felix Boria, Teresa Castellanos, Monica Gutierrez, Enrique Chacon, Nabil Manzour, Jose Angel Minguez, Nerea Martin-Calvo, Juan Luis Alcazar, Luis Chiva
OBJECTIVE: The aim of this study was to compare the incidence of intra-operative and post-operative complications in open and minimally invasive radical hysterectomy for patients with early-stage cervical cancer. METHODS: Data were collected from the SUCCOR database of 1272 patients with stage IB1 cervical cancer (International Federation of Gynecology and Obstetrics (FIGO), 2009) who underwent radical hysterectomy in Europe between January 2013 and December 2014...
February 5, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38666471/-ttn-mutation-in-endometrial-endometrioid-carcinoma-is-associated-with-poor-clinical-outcomes-and-high-tumor-mutation-burden
#3
JOURNAL ARTICLE
Lihong Li, Pinli Yue, Jiarun Zhu, Luyuan Li, Kaipeng Wang, Guangwen Yuan, Yan Song
Endometrioid endometrial carcinoma (EEC) stands as a prevalent gynecologic malignancy in developed regions. However, predicting relapse cases remains challenging, necessitating the identification of a novel biomarker for EEC relapse. The assessment of tumor mutational burden (TMB) is pivotal for immunotherapy in EEC patients. However, both whole-exome sequencing (WES) and targeted sequencing encountered application-related difficulties. In light of this, standardized and simplified techniques for TMB measurement are imperative...
April 26, 2024: Cancer Investigation
https://read.qxmd.com/read/38664269/gynecologic-perivascular-epithelioid-cell-tumors-pecomas-a-review-of-recent-evidence
#4
REVIEW
Gabriel Levin, Mariana Pilon Capella, Raanan Meyer, Yoav Brezinov, Walter H Gotlieb
Gynecologic perivascular epithelioid cell (PEC) tumors, or 'PEComas,' represent a rare and intriguing subset of tumors within the female reproductive tract. This systematic literature review aims to provide an updated understanding of gynecologic PEComas based on available literature and data. Although PEComa is rare, there are varied tumor-site presentations across gynecologic organs, with uterine PEComas being the most prevalent. There is scarce high-quality literature regarding gynecologic PEComa, and studies on malignant PEComa underscore the challenges in diagnosis...
April 25, 2024: Archives of Gynecology and Obstetrics
https://read.qxmd.com/read/38664025/-effects-of-applying-human-umbilical-cord-mesenchymal-stem-cell-exosomes-through-different-pathways-to-treat-full-thickness-skin-defect-wounds-in-mice
#5
JOURNAL ARTICLE
H Y Wang, T Ba, B Zhou, Z Q Yan, R J Wang, L Y Liu
Objective: To investigate the effects of human umbilical cord mesenchymal stem cell (hUCMSC) exosomes in the treatment of full-thickness skin defect wounds in mice through local wound application, subcutaneous injection at the wound margin, and tail vein injection, and to explore the optimal administration route of hUCMSC exosomes for wound treatment. Methods: This study was an experimental study. hUCMSC exosomes were extracted from the discarded umbilical cord tissue of three normal delivery women aged 25-35 years in the Department of Obstetrics and Gynecology of Baogang Hospital of Inner Mongolia and successfully identified...
April 20, 2024: Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi
https://read.qxmd.com/read/38662438/bridging-the-gap-from-bench-to-bedside-a-call-for-in-vivo-preclinical-models-to-advance-endometrial-cancer-and-cervical-cancer-immuno-oncology-research
#6
JOURNAL ARTICLE
Laura Chambers, Paulina Haight, Julia Chalif, Yogita Mehra, Daniel Spakowicz, Floor J Backes, Casey M Cosgrove, David M O'Malley, Roberto Vargas, Bradley R Corr, Victoria L Bae-Jump, Rebecca C Arend
Advanced-stage endometrial and cervical cancers are associated with poor outcomes despite contemporary advances in surgical techniques and therapeutics. Recent clinical trial results have led to a shift in the treatment paradigm for both malignancies, where immunotherapy is now incorporated in the upfront setting for most patients with advanced endometrial and cervical cancers as the standard of care. Impressive response rates have been observed, but unfortunately, a subset of patients do not benefit from immunotherapy, and survival remains poor...
April 25, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38661560/human-papillomavirus-associated-multiphenotypic-carcinoma-first-description-of-a-vulval-case
#7
JOURNAL ARTICLE
Charlotte C Currie, Darren Leaning, W Glenn McCluggage, Emma Spoor
Human papillomavirus (HPV)-associated multiphenotypic sinonasal carcinoma is a rare and recently described epithelial neoplasm exhibiting myoepithelial differentiation and morphological overlap with salivary gland neoplasms, especially adenoid cystic carcinoma; it is commonly associated with HPV, especially type 33. It has mainly been reported in the nasal cavity and paranasal sinuses with a single case reported in the breast. Herein, we report the first vulval example in a 47-year-old patient who presented with a large craggy mass in the region of the Bartholin gland...
April 9, 2024: International Journal of Gynecological Pathology
https://read.qxmd.com/read/38661558/high-grade-serous-carcinoma-occurring-in-a-serous-cystadenoma-on-the-background-of-a-serous-tubal-intraepithelial-carcinoma-stic-like-lesion-a-case-report-with-literature-review
#8
JOURNAL ARTICLE
Filipp Vladimirovich Novikov, Aleksandr Grigorevich Anufriev, Gennadii Dmitrievich Efremov
At present, the prevailing concept is that high-grade serous carcinoma (HGSC) arises from the fallopian tubes (FTs). We report an HGSC case occurring in a serous ovarian cyst against the background of a serous tubal intraepithelial carcinoma (STIC)-like lesion. We also provide a literature review that contains references to clinical cases of the occurrence of STIC-like lesions in the ovary and phylogenetic studies that do not always reveal obvious bonds between early dysplastic serous lesions and HGSC. The article discusses cases of association between HGSCs of serous borderline tumors (SBTs) and low-grade serous carcinomas (LGSCs) in the context of their possible histogenetic relationship...
April 18, 2024: International Journal of Gynecological Pathology
https://read.qxmd.com/read/38661526/clinicopathologic-characteristics-of-a-single-institution-cohort-of-ovarian-adult-granulosa-cell-tumors-with-biomarker-and-therapeutic-implications-utilizing-the-detection-of-androgen-estrogen-and-progesterone-hormone-receptor-expression-by-immunohistochemistry
#9
JOURNAL ARTICLE
Michelle Moh, Andrii Puzyrenko, Rebekah Summey, Janet S Rader, Genaro Enrique Herrera Cano, Jennifer V Gavina, Hallgeir Rui, Yunguang Sun, Elizabeth Hopp
Adult granulosa cell tumors (AGCTs) are rare ovarian tumors with generally good prognosis after surgical resection; however, they do have recurrence potential. Therapeutic and management options for recurrences are currently limited, and the need for expanded adjuvant therapies is increasingly recognized. Anti-hormonal therapy is being explored as an option, which relies on the detection and assessment of hormone receptor expression (androgen, estrogen, and progesterone receptors) as a biomarker and therapeutic target...
March 27, 2024: International Journal of Gynecological Pathology
https://read.qxmd.com/read/38658024/biomarker-driven-targeted-therapy-in-patients-with-recurrent-platinum-resistant-epithelial-ovarian-cancer-bright-protocol-for-an-open-label-multicenter-umbrella-study
#10
JOURNAL ARTICLE
Yu Xu, Fan Xiong, Huayi Li, Hong Zheng, Jie Jiang, Qingshui Li, Guiling Li, Weidong Zhao, Rong Li, Jundong Li, Rong Xie, Ruifang An, Huifeng Zhang, Qinglei Gao
BACKGROUND: Platinum-resistant, recurrent ovarian cancer has an abysmal prognosis with limited treatment options. Poly-(ADP-ribose)-polymerase (PARP), angiogenesis, and immune checkpoint inhibitors might improve the outcomes of platinum-resistant, recurrent ovarian cancer, but accurate patient selections for those therapies remain a significant clinical challenge. PRIMARY OBJECTIVE: To evaluate the efficacy and safety of biomarker-driven combinatorial therapies of pamiparib, tislelizumab, bevacizumab, and nab-paclitaxel in platinum-resistant, recurrent ovarian cancer...
April 23, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38658022/circulating-tumor-dna-as-a-biomarker-for-predicting-progression-free-survival-and-overall-survival-in-patients-with-epithelial-ovarian-cancer-a-systematic-review-and-meta-analysis
#11
JOURNAL ARTICLE
Cristina Taliento, Giampaolo Morciano, Camilla Nero, Wouter Froyman, Giuseppe Vizzielli, Matteo Pavone, Stefano Salvioli, Mara Tormen, Francesco Fiorica, Gennaro Scutiero, Giovanni Scambia, Carlotta Giorgi, Pantaleo Greco, Paolo Pinton
OBJECTIVES: Circulating tumor DNA (ctDNA) is emerging as a potential prognostic biomarker in multiple tumor types. However, despite the many studies available on small series of patients with ovarian cancer, a recent systematic review and meta-analysis is lacking. The objective of this study was to determine the association of ctDNA with progression-free-survival and overall survival in patients with epithelial ovarian cancer. METHODS: An electronic search was conducted using PubMed (MEDLINE), Embase, CENTRAL (Cochrane Library), and CINAHL-Complete from January 2000 to September 15, 2023...
April 23, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38658021/prognostic-value-of-molecular-classification-in-stage-iv-endometrial-cancer
#12
JOURNAL ARTICLE
Margot H Uijterwaal, Dionne van Dijk, Christianne A R Lok, Cor D De Kroon, Jenneke C Kasius, Ronald Zweemer, Cornelis G Gerestein, Nanda Horeweg, Tjalling Bosse, Jacolien van der Marel, Linda S Nooij
OBJECTIVES: Multiple studies have proven the prognostic value of molecular classification for stage I-III endometrial cancer patients. However, studies on the relevance of molecular classification for stage IV endometrial cancer patients are lacking. Hypothetically, poor prognostic molecular subtypes are more common in higher stages of endometrial cancer. Considering the poor prognosis of stage IV endometrial cancer patients, it is questionable whether molecular classification has additional prognostic value...
April 23, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38658020/endometrial-cancer-with-positive-sentinel-lymph-nodes-pathologic-characteristics-of-metastases-as-predictors-of-extent-of-lymphatic-dissemination-and-prognosis
#13
JOURNAL ARTICLE
Giorgia Dinoi, Khaled Ghoniem, Yajue Huang, Valentina Zanfagnin, Giuseppe Cucinella, Carrie Langstraat, Gretchen Glaser, Amanika Kumar, Amy Weaver, Michaela McGree, Francesco Fanfani, Giovanni Scambia, Andrea Mariani
OBJECTIVES: To assess predictors of extensive lymph node dissemination and non-vaginal recurrence in patients with endometrial cancer with positive sentinel lymph nodes (SLNs). METHODS: Patients with endometrial cancer who underwent primary surgery with SLN mapping and had at least one positive node between October 2013 and May 2019 were included. Positive SLNs were reviewed, and cases were classified according to the location of the metastasis (extracapsular vs intracapsular), and the size of the largest SLN metastasis (isolated tumor cells, micrometastasis, macrometastasis)...
April 23, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38658016/validating-the-diagnostic-accuracy-of-an-mri-based-scoring-system-for-differentiating-benign-uterine-leiomyomas-from-leiomyosarcomas
#14
JOURNAL ARTICLE
Maryam Al Khuri, Ishaq Al Salmi, Hawra Al Ajmi, Aymen Al Hadidi, Abdullah Alabousi, Ehsan Haider, Pooja Vasudev, Ahmed Al Salmi, Sachin Jose, Nasser Alrahbi
OBJECTIVE: Uterine leiomyomas are the most common benign uterine tumors. They are difficult to distinguish from their malignant counterparts-smooth muscle tumors of unknown malignant potential (STUMP) and leiomyosarcoma. The purpose of this study is to propose and validate the diagnostic accuracy of the MRI-based Oman-Canada Scoring System of Myometrial Masses (OCSSMM) to differentiate uterine leiomyomas from STUMP/leiomyosarcomas. METHODS: This is a retrospective study performed at two tertiary care centers...
April 23, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38657573/cct6a-regulates-cervical-cancer-cell-glycolysis-and-proliferation-under-hypoxic-conditions-via-the-tcab1-tert
#15
JOURNAL ARTICLE
Yu Wang, Hongli Wang
OBJECTIVES: Cervical cancer is one of the most common female malignancies worldwide, a hypoxic microenvironment usually causes enhanced viability and glycolytic capacity of cervical cancer cells. The aim of this study was to investigate the association between chaperonin containing t-complex polypeptide 1 subunit 6A (CCT6A) and cell proliferation as well as hypoxic glycolysis. DESIGN: Bioinformatics analysis was conducted to explore the association between cervical cancer and its partner protein under hypoxic conditions, namely CCT6A...
April 24, 2024: Gynecologic and Obstetric Investigation
https://read.qxmd.com/read/38657450/outcomes-in-ovarian-sertoli-leydig-cell-tumor-a-report-from-the-international-pleuropulmonary-blastoma-dicer1-and-ovarian-and-testicular-stromal-tumor-registries
#16
JOURNAL ARTICLE
Alexander T Nelson, Anne K Harris, Dave Watson, Junne Kamihara, Kenneth S Chen, Jennifer N Stall, Kyle M Devins, Robert H Young, Damon R Olson, Paige H R Mallinger, Sarah G Mitchell, Lindsey M Hoffman, Gail Halliday, Amina M Suleymanova, Julia L Glade Bender, Yoav H Messinger, Cynthia E Herzog, Amanda L Field, A Lindsay Frazier, Douglas R Stewart, Louis P Dehner, D Ashley Hill, Deborah F Billmire, Dominik T Schneider, Kris Ann P Schultz
OBJECTIVE: Sertoli-Leydig cell tumors (SLCTs) are rare sex cord-stromal tumors, representing <0.5% of all ovarian tumors. We sought to describe prognostic factors, treatment and outcomes for individuals with ovarian SLCT. METHODS: Individuals with SLCT were enrolled in the International Pleuropulmonary Blastoma/DICER1 Registry and/or the International Ovarian and Testicular Stromal Tumor Registry. Medical records were systematically abstracted, and pathology was centrally reviewed when available...
April 22, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38656879/a-novel-prognostic-signature-based-on-cancer-stemness-and-metabolism-related-genes-for-cervical-squamous-cell-carcinoma-and-endocervical-adenocarcinoma
#17
JOURNAL ARTICLE
Yaokai Wang, Yuanyuan Han, Liangzi Jin, Lulu Ji, Yanxiang Liu, Min Lin, Sitong Zhou, Ronghua Yang
BACKGROUND: CESC is the second most commonly diagnosed gynecological malignancy. Given the pivotal involvement of metabolism-related genes (MRGs) in the etiology of multiple tumors, our investigation aims to devise a prognostic risk signature rooted in cancer stemness and metabolism. METHODS: The stemness index based on mRNA expression (mRNAsi) of samples from the TCGA dataset was computed using the One-class logistic regression (OCLR) algorithm. Furthermore, potential metabolism-related genes related to mRNAsi were identified through weighted gene co-expression network analysis (WGCNA)...
April 23, 2024: Aging
https://read.qxmd.com/read/38654239/a-novel-tcga-validated-programmed-cell-death-related-signature-of-ovarian-cancer
#18
JOURNAL ARTICLE
Xintong Cai, Jie Lin, Li Liu, Jianfeng Zheng, Qinying Liu, Liyan Ji, Yang Sun
BACKGROUND: Ovarian cancer (OC) is a gynecological malignancy tumor with high recurrence and mortality rates. Programmed cell death (PCD) is an essential regulator in cancer metabolism, whose functions are still unknown in OC. Therefore, it is vital to determine the prognostic value and therapy response of PCD-related genes in OC. METHODS: By mining The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx) and Genecards databases, we constructed a prognostic PCD-related genes model and performed Kaplan-Meier (K-M) analysis and Receiver Operating Characteristic (ROC) curve for its predictive ability...
April 23, 2024: BMC Cancer
https://read.qxmd.com/read/38653864/nivolumab-for-mismatch-repair-deficient-or-hypermutated-gynecologic-cancers-a-phase-2-trial-with-biomarker-analyses
#19
JOURNAL ARTICLE
Claire F Friedman, Beryl L Manning-Geist, Qin Zhou, Tara Soumerai, Aliya Holland, Arnaud Da Cruz Paula, Hunter Green, Melih Arda Ozsoy, Alexia Iasonos, Travis Hollmann, Mario M Leitao, Jennifer J Mueller, Vicky Makker, William P Tew, Roisin E O'Cearbhaill, Ying L Liu, Maria M Rubinstein, Tiffany Troso-Sandoval, Stuart M Lichtman, Alison Schram, Chrisann Kyi, Rachel N Grisham, Pamela Causa Andrieu, E John Wherry, Carol Aghajanian, Britta Weigelt, Martee L Hensley, Dmitriy Zamarin
Programmed death-1 (PD-1) inhibitors are approved for therapy of gynecologic cancers with DNA mismatch repair deficiency (dMMR), although predictors of response remain elusive. We conducted a single-arm phase 2 study of nivolumab in 35 patients with dMMR uterine or ovarian cancers. Co-primary endpoints included objective response rate (ORR) and progression-free survival at 24 weeks (PFS24). Secondary endpoints included overall survival (OS), disease control rate (DCR), duration of response (DOR) and safety...
April 23, 2024: Nature Medicine
https://read.qxmd.com/read/38653587/congenital-and-gynecological-tumors-a-review
#20
JOURNAL ARTICLE
Shady A Saleem, Fatma El-Zahraa A Mustafa, Hanan H Abd-Elhafeez, Gilan A Ahmed
Congenital tumors are rare, and malignant congenital tumors are uncommon. Benign tu,mors might be life-threatening, depending on the location and size of the tumor. Different factors affect congenital tumors, such as maternal and placental hormones and environmental factors such as drugs, radiation, and infection. Developing fetal imaging methods and continuous follow-up during pregnancy are important factors in congenital tumor prognosis. Ultrasound is the most common method used for fetal evaluation. The complementary evaluation method is MRI...
April 16, 2024: European Journal of Surgical Oncology
keyword
keyword
54797
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.